Leukæmi kliniske forsøg i Texas
31 studier for Leukæmi søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 6, Houston
RekruttererFase 3
Alder 18 til 71 · Alle køn · Opdateret 23. sep. 2026 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 1 til 25 · Alle køn · Opdateret 23. sep. 2026 · NCT05645718Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
RekruttererFase 1
Op til 75 år · Alle køn · Opdateret 16. sep. 2026 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
- MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06229912Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Houston
RekruttererFase 3
Alder 18 til 18 · Alle køn · Opdateret 8. sep. 2026 · NCT07509151First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Cook Children's Medical Center, Fort Worth
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT07586618Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07284433Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Texas Oncology-Austin Midtown, Austin
- Texas Oncology-Presbyterian Cancer Center, Dallas
- University of Texas, Houston
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
RekruttererFase 2
Alder 7 til 25 · Alle køn · Opdateret 19. aug. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT06137118Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 60 og opefter · Alle køn · Opdateret 16. jul. 2026 · NCT01515527CD4CAR for CD4+ Leukemia and Lymphoma
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 12 og opefter · Alle køn · Opdateret 24. jun. 2026 · NCT03829540A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 22. jun. 2026 · NCT07356154A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
- M D Anderson Cancer Center, Houston
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 20. maj 2026 · NCT05011045Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- University of Texas Health Science Center at San Antonio, San Antonio
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT05536349A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin, Austin
- UT Southwestern - Simmons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 20. feb. 2026 · NCT05745285cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT05366881Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 31. okt. 2025 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The University of Texas M.D. Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. nov. 2024 · NCT06034275Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.